Approaches to the pharmacotherapy of angina pectoris have previously centred on the
concept that a transient imbalance between myocardial oxygen “demand” and supply within …

Perhexiline was introduced about 30 years ago and rapidly gained a reputation for efficacy
in the management of angina pectoris. However, hepatic and neurological adverse effects …

Background: Perhexiline, originally used as a first-line prophylactic antianginal agent, is now
regarded primarily as a treatment for otherwise refractory myocardial ischemia. Recent …

Perhexiline maleate, which causes inhibition of myocardial fatty acid catabolism with a
concomitant increase in glucose utilization, is particularly useful in the management of …

Perhexiline is a unique anti-anginal agent that is frequently used in the treatment of chronic
refractory angina. Its utility has been limited because of its complex pharmacokinetics that …

Purpose Perhexiline is a prophylactic anti-ischaemic agent with weak calcium antagonist
effect which has been increasingly utilised in the management of refractory angina. The …

Perhexiline maleate (Pexid®) which has been in general use in France with good results for
the treatment of angina pectoris since 1973, may be associated with severe side effects …

Aims 1) To develop an estimate of oral clearance (/F) for the antianginal agent perhexiline
based on the ratio of cis‐OH‐perhexiline metabolite/parent perhexiline plasma …

Despite large gains in the medical and surgical treatment of angina pectoris in the past two
decades, many patients are refractory to conventional medical therapy and are unsuitable …

In heart failure with reduced ejection fraction, mechanical work produced by the left ventricle
to support the systemic circulation decreases over time despite relatively constant …